Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 337.16% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Needham & Company LLC dropped their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Stock Up 12.6 %

Shares of ESPR opened at $3.66 on Tuesday. The business has a 50-day simple moving average of $2.22 and a two-hundred day simple moving average of $2.18. The stock has a market cap of $721.15 million, a price-to-earnings ratio of -5.72 and a beta of 1.01. Esperion Therapeutics has a 52 week low of $1.35 and a 52 week high of $3.81.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently made changes to their positions in the business. Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after buying an additional 3,688,796 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Esperion Therapeutics in the 3rd quarter valued at about $606,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.